arrow
B

Benjamin Kasenda

university of basel
H指数:39
被引数:5,237

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Tumor Genomic Profiles Associated with Clinical Benefit from Immune Checkpoint Inhibitor Therapy – An Exploratory Analysis of the INFINITY Precision Oncology Registry

肿瘤基因组特征与免疫检查点抑制剂治疗临床获益的关联性分析——一项基于INFINITY精准肿瘤学登记研究的探索性分析

2026-08-260
OA
IGLV3-21R110-directed bispecific antibodies activate T cells and promote killing in ahigh-risk subset of chronic lymphocytic leukemia

Fischer, C.; Chen, S.S.; Nimmerfroh, J.; Eugster, A.; Stucheli, S.; Schultheiss, C.; Widmer, C.; Heim, D.; Kasenda, B.; Passweg, J.; et al. IGLV3-21(R110)靶向双特异性抗体可激活T细胞并促进在慢性淋巴细胞白血病高风险亚群中的杀伤作用。Haematologica 2025. [Google Scholar] [CrossRef]

2026-02-012
OA
Mixed-methods process evaluation of ctDNA use to guide decision-making in patients with advanced solid cancers: study protocol for a substudy of the LIQPLAT trial

ctDNA用于指导晚期实体癌患者决策的混合方法过程评估: LIQPLAT试验子研究的研究方案

2025-10-270
OA
High-dose chemotherapy and autologous haematopoietic stem-cell transplantation in older, fit patients with primary diffuse large B-cell CNS lymphoma (MARTA): a single-arm, phase 2 trial
2024-03-016
PRE
The INFINITY study protocol: a retrospective cohort study on decision making and clinical impact of biomarker-driven precision oncology in routine clinical practice

INFINITY研究方案: 生物标志物驱动的精准肿瘤学在常规临床实践中的决策和临床影响的回顾性队列研究

2023-06-130
OAAI
Targeting cancer glycosylation repolarizes tumor-associated macrophages allowing effective immune checkpoint blockade
2022-11-0290
OA
European Association of Neuro-Oncology (EANO) guidelines for treatment of primary central nervous system lymphoma (PCNSL)
2022-08-1261
OA
Nonregistration, discontinuation, and nonpublication of randomized trials: A repeated metaresearch analysis

随机试验的非注册、终止和非发表: 重复的元研究分析

2022-04-2726
OAAI
Reporting quality of trial protocols improved for non-regulated interventions but not regulated interventions: A repeated cross-sectional study
2021-11-018
OA
Clinical Trial Evidence Supporting US Food and Drug Administration Approval of Novel Cancer Therapies Between 2000 and 2016

支持美国食品和药物管理局批准2000和2016之间的新型癌症疗法的临床试验证据

2020-11-1065
OAAI
Analysis of Driver Mutational Hot Spots in Blood-Derived Cell-Free DNA of Patients with Primary Central Nervous System Lymphoma Obtained before Intracerebral Biopsy
2020-10-0114
OAAI